• SPX
  • $5,633.46
  • 0.01 %
  • $0.37
  • DJI
  • $41,540.87
  • -0.2 %
  • -$81.22
  • N225
  • $36,203.22
  • -1.03 %
  • -$378.54
  • FTSE
  • $8,309.86
  • 0.38 %
  • $31.42
  • IXIC
  • $17,608.52
  • 0.09 %
  • $16.39
GlycoMimetics, Inc. (GLYC) Stock Price, News & Analysis

GlycoMimetics, Inc. (GLYC) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.17

-$0

(1.73%)

Day's range
$0.16
Day's range
$0.17
50-day range
$0.155
Day's range
$0.33
  • Country: US
  • ISIN: US38000Q1022
52 wk range
$0.16
Day's range
$3.53


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -1,355.38
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (GLYC)
  • Company GlycoMimetics, Inc.
  • Price $0.17
  • Changes Percentage (1.73%)
  • Change -$0
  • Day Low $0.16
  • Day High $0.17
  • Year High $3.53

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 10/31/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.58
  • Trailing P/E Ratio -0.44
  • Forward P/E Ratio -0.44
  • P/E Growth -0.44
  • Net Income $-36,899,420

Income Statement

Quarterly

Annual

Latest News of GLYC

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.